SK CAPITAL to acquire SWIXX BIOPHARMA

SK CAPITAL has agreed to acquire SWIXX BIOPHARMA in a transaction announced on 8 March 2026. The deal involves the biopharmaceutical sector, specifically within the wholesale of pharmaceutical goods classification. No financial consideration or specific deal value was disclosed in the available information. The target company operates within the pharmaceutical industry, though its precise country of origin remains unreported.

The transaction is currently in the review phase with regulatory authorities. Completion has not yet been confirmed as the deal status remains pending further approvals. All parties are proceeding with the acquisition process while awaiting the final regulatory decision. The deal structure involves a direct acquisition by the named buyer without a disclosed management buyout or merger of equals arrangement. Further details regarding the specific terms of the agreement are not available at this time.